Form 4: ANI Pharma CEO Lalwani Receives Significant Stock Award

ANI Pharmaceuticals CEO Nikhil Lalwani was granted 75,592 shares of common stock as a restricted stock award, increasing his direct beneficial ownership.

Summary

• Nikhil Lalwani, President & CEO and Director of ANI Pharmaceuticals Inc. (ANIP), reported changes in beneficial ownership.
• On February 26, 2026, Lalwani acquired 75,592 shares of common stock at a price of $77.15 per share as a restricted stock award.
• This restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• Following this acquisition, Lalwani's direct beneficial ownership increased to 434,166 shares.
• On February 28, 2026, 12,217 shares were disposed of at $73.9 per share, withheld for tax purposes in connection with the vesting of 23,883 shares of previously reported restricted stock.
• After the tax-related disposition, Lalwani's direct beneficial ownership stands at 421,949 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and alignment of interests, with no unexpected negative implications.

Positives

• Grant of 75,592 restricted stock units to the President & CEO, aligning management's interests with shareholders.
• The award price of $77.15 per share reflects a valuation at the time of grant.

Negatives

• Disposition of 12,217 shares for tax withholding purposes, which is a standard practice upon vesting of restricted stock and not indicative of negative sentiment.

Future Outlook

The restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026, indicating future equity compensation realization.

Industry Context

StockSavvy.ai notes that restricted stock awards are a common form of executive compensation in the pharmaceutical industry, designed to incentivize long-term performance and align management's interests with shareholder value creation. This type of grant is typical for a President & CEO.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with long-term company performance due to equity ownership. Potential minor dilution from new share issuance, but this is standard for equity compensation.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• First annual vesting installment of the 75,592 restricted stock award on February 26, 2027.
• Subsequent annual vesting installments on February 26, 2028, February 26, 2029, and February 26, 2030.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Nikhil Lalwani, Insider Transaction, Form 4, Restricted Stock Award, CEO Compensation, Stock Ownership, Equity Grant